All In Biotech

Free tool

FAERS Monitor: Halcion

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017892 or its brand name (Halcion, Triazolam). Reports on generic versions are filed under their own applications.

Reports

4,040

Serious

3,259

81% of reports

Hospitalization

1,627

Death reported

662

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug abuse336
  • drug ineffective288
  • toxicity to various agents220
  • sopor208
  • overdose182
  • completed suicide172
  • fatigue165
  • nausea163
  • malaise155
  • drug interaction152
  • fall144
  • dizziness135
  • anxiety132
  • insomnia132
  • somnolence130

Reports by year received

View as table
YearReports
200494
200576
200676
200759
200867
200976
2010119
2011129
2012164
2013185
2014225
2015250
2016317
2017288
2018301
2019276
2020229
2021221
2022177
2023262
2024160
2025143
2026146

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
soporSignal20883.072.616,519
drug abuseSignal33621.119.06,411
completed suicideSignal17210.89.31,517
toxicity to various agentsSignal2206.86.01,090
drug interactionSignal1525.04.3484
overdoseSignal1824.43.8478
somnolenceSignal1303.42.8215
insomniaSignal1322.62.2128
anxietySignal1322.42.0110
fallSignal1442.31.9101
malaise1551.81.660
dizziness1351.41.216
drug ineffective2881.11.05
fatigue1651.11.02
nausea1631.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.